Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions

This study has been completed.
Information provided by (Responsible Party):
Boston Scientific Corporation Identifier:
First received: August 31, 2006
Last updated: February 1, 2012
Last verified: February 2012